First successful pregnancy outcome after twelve abortions in a Tunisian-woman with the rare p phenotype.
Anti-PP1P(k)
Plasmapheresis
Recurrent miscarriages
p phenotype
Journal
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
ISSN: 1953-8022
Titre abrégé: Transfus Clin Biol
Pays: France
ID NLM: 9423846
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
08
02
2021
revised:
09
06
2021
accepted:
10
06
2021
pubmed:
22
6
2021
medline:
29
10
2021
entrez:
21
6
2021
Statut:
ppublish
Résumé
Anti-PP1P k alloantibody, is produced in the serum of individuals with the rare p phenotype. It is associated with severe haemolytic transfusion reactions, recurrent spontaneous early abortions as well as haemolytic disease of the foetus and newborn. Anti-PP1P k alloimmunization in pregnancy differ from others in their physiopathology. It seems that the placenta would be the main target of anti-PP1P k antibody. This report concerns a 35 year old female, with a history of a high incidence (12) of early and recurrent miscarriages. She was found to have the extremely rare p phenotype and anti-PP1P k antibody in her serum. Her 13th pregnancy was successfully managed by plasmapheresis. No substitution fluid was added. Oral hydration was recommended before and after the apheresis sessions. 12 plasmapheresis cycles were performed before a healthy term female infant weighing 3kg600g, was delivered by caesarean section at 38 weeks of gestation. Plasmapheresis seems to be the treatment of choice in the management of anti-PP1P k fetomaternal incompatibilities. However in this case, we opted for an original and less expensive protocol. We did resort, neither to substitution fluid nor to intravenous immunoglobulin.
Identifiants
pubmed: 34153474
pii: S1246-7820(21)00085-9
doi: 10.1016/j.tracli.2021.06.003
pii:
doi:
Substances chimiques
Isoantibodies
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
283-286Informations de copyright
Copyright © 2021 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.